H.C. Wainwright lifts Instil Bio stock target to $125

H.C. Wainwright increased its price target on Instil Bio (TIL) to $125 from $105, reiterating a Buy rating, after positive Phase 1/2 data for AXN-2510, a non-small cell lung cancer treatment being developed with ImmuneOnco. The analyst cited a 23% overall response rate in NSCLC patients and competitive efficacy compared to other bispecifics, particularly in patients with low PD-L1 expression, leading to an increased probability of approval from 25% to 35%. Recent activity in the bispecific antibody market, including Pfizer's $1.25B upfront deal for 3SBio's candidate, further underscores the value in this therapeutic area.

Analysis

H.C. Wainwright has increased its price target for Instil Bio Inc. (TIL) to $125 from a previous $105, while reaffirming a Buy rating, following the release of positive Phase 1/2 dose escalation data for AXN-2510 in non-small cell lung cancer (NSCLC). The study, involving 51 patients with solid tumors, reported a 23% overall response rate (ORR) for AXN-2510 in 13 NSCLC patients who had received prior therapies; median progression-free survival (mPFS) was not yet reported. The analyst highlighted AXN-2510's competitive efficacy, particularly in patients with low PD-L1 expression, noting its 23% ORR favorably compares to BNT327's 13% ORR in a similar population, though it is below ivonescimab's 33% ORR observed in a distinct EGFR/ALK/ROS wild-type patient group. Consequently, H.C. Wainwright raised the probability of approval for AXN-2510 from 25% to 35%. Instil Bio's shares, currently trading at $21.02, have demonstrated significant momentum with a 43.68% gain over the past week and a 90.48% return over the last year; the new target implies substantial upside, with the broader analyst price target consensus ranging from $51 to $180. The company, with a market capitalization of $137.17 million, is reported by InvestingPro to have a 'GOOD' overall financial health score and maintains a strong balance sheet with more cash than debt. This development occurs amidst a backdrop of vigorous M&A and licensing activity in the bispecific antibodies market, exemplified by Pfizer's recent deal involving a $1.25 billion upfront payment for 3SBio's candidate, which underscores the high strategic value and clinical interest in this therapeutic class.

Key Decisions for Investors

• Investors should consider the significant potential upside indicated by H.C. Wainwright's $125 price target for Instil Bio, which is substantially above the current $21.02 share price, supported by positive early-stage clinical data for AXN-2510 and strong recent stock performance.
• It is crucial to weigh the early nature of the AXN-2510 data (Phase 1/2), the pending median progression-free survival results, and the analyst's current approval probability estimate of 35%, all of which represent typical risks in biotechnology investments.
• Monitoring upcoming clinical trial readouts for AXN-2510, including data on other tumor types from partner ImmuneOnco, alongside competitive advancements and ongoing transactional trends in the bispecific antibody sector, will be vital for assessing the investment thesis.